Advances in the Molecular Genetics of Metachromatic Leukodystrophy

  • V. Gieselmann
  • K. von Figura
Chapter

Summary

Metachromatic leukodystrophy is a lysosomal storage disorder caused by the deficiency of arylsulphatase A (EC 3.1.6.1). This results in the intralysosomal storage of cerebroside sulphate, which leads to a progressive demyelination of the nervous system. The patients usually die within a few years from the onset of symptoms. Clinically, there are different forms of the disease and the molecular basis for this heterogeneity is unknown. The gene for arylsulphatase A has recently been cloned and provides a necessary tool for the exact description of the molecular defects occurring in the different forms of metachromatic leukodystrophy. Metachromatic leukodystrophy can also be caused by the deficiency of an arylsulphatase A activator protein (sphingolipid activator protein B). The cDNA for the precursor of this protein has been isolated and a mutant cDNA of one patient has been analysed. A substantial arylsulphatase A deficiency can also occur in healthy individuals, a phenotype termed pseudodeficiency. Two concurrent mutations have been identified in this low arylsulphatase A activity allele. This permitted the development of a rapid assay which allows the detection of the pseudodeficiency allele. Bone marrow transplantation has been tried in several metachromatic leukodystrophy patients and there is evidence that this treatment might slow or even halt the progression of the disease. A final conclusion as to whether bone marrow transplantation is a suitable therapy for metachromatic leukodystrophy cannot be drawn yet.

Keywords

Bone Marrow Transplantation Polyadenylation Signal Metachromatic Leukodystrophy Potential Glycosylation Site Twitcher Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Austin, J. Metachromatic sulfatides in cerebral white matter and kidney. Proc. Soc. Exp. Biol. Med. 100 (1959) 361PubMedGoogle Scholar
  2. Austin, J. H., Balasubramanian, A. S., Patabiramen, T. N., Saraswathi, S., Basu, D. K.and Bachhawat, B. K. A controlled study of enzymatic activities in three human disorders of glycolipid metabolism. J. Neurochem. 10 (1963) 805PubMedCrossRefGoogle Scholar
  3. Bach, G. and Neufeld, E. F. Synthesis and maturation of cross reactive glycoprotein in fibroblasts deficient in arylsulfatase A activity. Biochem. Biophys. Res. Commun. 112 (1983) 198–205PubMedCrossRefGoogle Scholar
  4. Baldinger, S., Pierpont, M. E. and Wenger, D. A. Pseudodeficiency of arylsulfatase A: a counselling dilemma. Clin. Genet. 31 (1987) 70–76PubMedCrossRefGoogle Scholar
  5. Bayerer, E., Ladisch, S., Philippart, M., Brill, N., Nuwer, M., Sparkes, R. S. and Feig, S. A. Bone marrow transplantation for metachromatic leukodystrophy. Lancet. 1 (1985) 471–473Google Scholar
  6. Dewji, N. N., Wenger, D. A., Fujibayashi, S., Donoviel, M., Esch, F., Hill, F. and O’Brien, J. S. Molecular cloning of the sphingolipid activator protein-1 (SAP 1). The sulfatide sulfatase activator. Biochem. Biophys. Res. Commun. 134 (1986) 989–994PubMedCrossRefGoogle Scholar
  7. Dewji, N. N., Wenger, D. A. and O’Brien, J. S. Nucleotide sequence of cloned cDNA for human sphingolipid activator protein precursor. Proc. Natl. Acad. Sci. USA. 84 (1987) 8652–8656PubMedCrossRefGoogle Scholar
  8. Dubois, G., Harzer, K. and Baumann, N. Very low arylsulfatase A and cerebroside sulfatase activities in leukocytes of healthy members of a metachromatic leukodystrophy family. Am. J. Hum. Genet. 29 (1977) 191–194PubMedGoogle Scholar
  9. Fischer, G. and Jatzkewitz, H. The activator of cerebroside sulphatase. Binding studies with enzyme and substrate demonstrating the detergent function of the activator protein. Biochim. Biophys. Acta. 481 (1977) 561–572PubMedGoogle Scholar
  10. Fluharty, A. L., Meek, W. E. and Kihara, H. Pseudoarylsulfatase A deficiency: evidence for a structurally altered enzyme. Biochem. Biophys. Res. Commun. 112 (1983) 191–197PubMedCrossRefGoogle Scholar
  11. Fujibayashi, S. and Wenger, D. A. Biosynthesis of the sulfatide/Gm I activator protein (SAP-1) in control and mutant cultured skin fibroblasts. Biochim. Biophys. Acta. 875 (1986) 554–562PubMedGoogle Scholar
  12. Fürst, W., Machleidt, W. and Sandhoff, K. The precursor of sulfatide activator protein is processed to three different proteins. Biol. Chem. Hoppe-Seyler. 369 (1988) 317–328PubMedCrossRefGoogle Scholar
  13. Gieselmann, V., Polten, A., Kreysing, J. and von Figura, K. Arylsulfatase pseudodeficiency: Loss of a polyadenylation signal and N-glycosylation site. Proc. Natl. Acad. Sci. USA. 86 (1989) 9436–9440PubMedCrossRefGoogle Scholar
  14. Gustayson, K. H. and Hagberg, B. The incidence and genetics of MLD in Northern Sweden. Acta Pediatr. Scand. 60 (1971) 585–590CrossRefGoogle Scholar
  15. Herz, B. and Bach, G. Arylsulfatase A in pseudodeficiency. Hum. Genet. 661 (1984) 147–150CrossRefGoogle Scholar
  16. Hohenschutz, C., Friedl, W., Schlör, K. H., Waheed, A., Conzelmann, E., Sandhoff, K. and Propping, P. Probable metachromatic leukodystrophy/pseudodeficiency compound heterozygote at an arylsulfatase A locus with neurologic and psychiatric symptomatology. Am. J. Med. Genet. 31 (1988) 169–175PubMedCrossRefGoogle Scholar
  17. Hohenschutz, C., Eich, P., Friedl, W., Waheed, A., Conzelmann, E. and Propping, P. Pseudodeficiency of arylsulfatase A: a common genetic polymorphism with possible disease implications. Hum. Genet. 82 (1989) 45–48PubMedCrossRefGoogle Scholar
  18. Hoogerbrugge, P. M., Suzuki, K., Suzuki, K. et al. Donor derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science. 239 (1988a) 1035–1038PubMedCrossRefGoogle Scholar
  19. Hoogerbrugge, P. M., Poorthuis, B. J., Romme, A. E., van de Kamp, J. J., Wagemaker, G. and von Bekkum, D. W. Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse. J. Clin. Invest. 81 (1988b) 1790–1794PubMedCrossRefGoogle Scholar
  20. Jatzkewitz, H. Zwei Typen von Cerebrosidschwefelsäureestern als sog. Prälipoide und Speichersubstanzen bei der metachromatischen Leukodystrophie. Z. Physiol. Chem. 311 (1958) 279CrossRefGoogle Scholar
  21. Kihara, H., Chen-Kung, H., Fluharty, A. L., Tsay, K. K., Hartlage, P. L. Prenatal diagnosis of metachromatic leukodystrophy in a family with pseudodarylsulfatase A deficiency by the cerebroside sulfate loading test. Pediatr. Res. 14 (1980) 224–227PubMedGoogle Scholar
  22. Kolodny, E. H., Moser, H. W. Sulfatide lipidosis: metachromatic leukodystrophy. In Stanbury, J. B., Wyngaarden, J. B., Fredrickson, D. S., Goldstein, J. L. and Brown, M. S. (eds.) The Metabolic Basis of Inherited Diseases. McGraw-Hill, New York, 1983, pp. 881–905Google Scholar
  23. Kretz, K., Ginns, E., Carson, G., Morimoto, S., Kishimoto, Y., Fluharty, A. L. and O’Brien, J. S. Characterization of a mutation in a family with saposin B deficiency. Am. Soc. Hum. Genet. (1989) abstractGoogle Scholar
  24. Kreysing, J., von Figura, K. and Gieselmann, V. The structure of the human arylsulfatase A gene. ESGLD Meeting (1989). Ittingen, abstractGoogle Scholar
  25. Krivit, W., Lipton, M. E., Lockman, L. A., Tsai, M., Dyck, P. J., Smith, S., Ramsay, N. K. C. and Kersey, J. Prevention of deterioration in metachromatic leukodystrophy by bone marrow transplantation. Am. J. Med. Sci. 294 (1987) 80–85PubMedCrossRefGoogle Scholar
  26. Li, S. C., Sonnino, S., Tettamanti. G. and Li, Y. T. Characterization of a non-specific activator protein for the enzymatic hydrolysis of glycolipids. J. Biol. Chem. 263 (1988) 6588–6591PubMedGoogle Scholar
  27. Mehl, E. and Jatzkewitz, H. Evidence for the genetic block in metachromatic leukodystrophy. Biochem. Biophys. Res. Commun. 19 (1965) 407PubMedCrossRefGoogle Scholar
  28. Morimoto, S., Martin, B. M., Kishimoto, Y. and O’Brien, J. S. Saposin D: A sphingomyelinase activator. Biochem. Biophys. Res. Commun. 156 (1988) 403–410PubMedCrossRefGoogle Scholar
  29. Morimoto, S., Martin, B. M., Yamamoto, Y., Kretz, K. A., O’Brien, J. S. and Kishimoto, Y. Saposin A: Second cerebrosidase activator protein. Proc. Natl. Acad. Sci. USA. 86 (1989) 3389–3393PubMedCrossRefGoogle Scholar
  30. Nakano, T., Sandhoff, K., Stümper, J., Christomanou, H. and Suzuki, K. Structure of full length cDNA coding for sulfatide activator, a co-(f-glucosidase and two other homologous proteins: Two alternate forms of the sulfatide activator. J. Biochem. Tokyo. 105 (1989) 152–154PubMedGoogle Scholar
  31. O’Brien, J. S., Kretz, K. A., Dewji, N. N., Wenger, D. A., Esch, F. and Fluharty, A. L. Coding of two sphingolipid activator proteins (SAP 1 and SAP 2) by the same genetic locus. Science. 234 (1988) 1098–1101CrossRefGoogle Scholar
  32. Peiffer, J. Über die metachromatischen Leukodystrophien (Typ Scholz). Arch. Psychiatr. Nerrenkr. 199 (1959) 386CrossRefGoogle Scholar
  33. Porter, N. T., Fluharty, A. L. and Kihara, H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science. 172 (1971) 1263–1265PubMedCrossRefGoogle Scholar
  34. Scholz, W. Klinische, pathologisch anatomische und erbbiologische Untersuchungen bei familiärer diffuser Hirnsklerose im Kindesalter. Z. Gesamte Neurol. Psychiatr. 99 (1925) 42CrossRefGoogle Scholar
  35. Shapiro, L. J., Aleck, K. A., Kaback, M. M., Itabashi, H., Desnick, R. J., Brand, N., Stevens, R. L., Fluharty, R. L. and Kihara, H. Metachromatic leukodystrophy without arylsulfatase A deficiency. Pediatr. Res. 13 (1979)PubMedCrossRefGoogle Scholar
  36. Stein, C., Gieselmann, V., Kreysing, J., Schmidt, B., Pohlmann, R., Waheed, A., Meyer, E. H., O’Brien, J. S. and von Figura, K. Cloning and expression of human arylsulfatase A. J. Biol. Chem. 264 (1989) 1252–1259PubMedGoogle Scholar
  37. Taylor, R. M., Farrow, B. R., Stewart, G. J., Healy, P. J. Enzyme replacement in nervous tissue after allogeneic bone marrow transplantation for fucosidosis in dogs. Lancet. 1 (1986) 772–774CrossRefGoogle Scholar
  38. Tonnesen, T., Vrang, C., Wiesmann, U., Christomanou, H. and Lou, H. O. Atypical metachromatic leukodystrophy? Hum. Genet. 67 (1984) 170–173PubMedCrossRefGoogle Scholar
  39. Waheed, A., Hasilik, A. and von Figura, K. Synthesis and processing of arylsulfatase A in human skin fibroblasts. Hoppe-Seyler’s Z. Physiol. Chem. 363 (1982) 425–430PubMedCrossRefGoogle Scholar
  40. Waheed, A., Steckel, F., Hasilik, A. and von Figura, K. Two allelic forms of human arylsulfatase A with different numbers of asparagine linked oligosaccharides. Am. J. Hum. Genet. 35 (1983) 228–233PubMedGoogle Scholar
  41. Wenger, D. A., De Gala, G., Williams, C., Taylor, H. A., Stevenson, R. E., Pruitt, J. R., Miller, J., Garen, P. D. and Balentine, J. D. Clinical pathological and biochemical studies on an infantile case of sulfatide/GMI activator protein deficiency. Am. J. Med. Genet. 33 (1989) 255–265PubMedCrossRefGoogle Scholar
  42. Yeager, A. M., Brennan, S., Tiffany, C., Moser, H. W. and Santos, W. G. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science. 225 (1984) 1052–1054PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Kluwer Academic Publishers 1990

Authors and Affiliations

  • V. Gieselmann
    • 1
  • K. von Figura
    • 1
  1. 1.Biochemie IIGeorg August UniversityGöttingenGermany

Personalised recommendations